The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Novavax’s COVID-19 Vaccine Filed in Japan: Takeda
Takeda Pharmaceutical said on December 16 that it has filed a new drug application for US partner Novavax’s COVID-19 vaccine in Japan. The Japanese company is currently preparing for its domestic production based on technology transfers, aiming to start supplies…
To read the full story
Related Article
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
- Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
- Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Datroway Accepted for European Review for 1st Line TNBC
December 19, 2025
- Recordati Snags Japan Rights to BMS’ Myelofibrosis Med Inrebic
December 19, 2025
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…